胰高血糖素样肽1受体激动剂治疗糖尿病肾病的临床研究进展  

Research progress of glucagon like peptide-1 receptor agonists in the treatment of diabetic nephropathy

作　　者：周亭 汪年松[1] 范瑛[1] ZHOU Ting;WANG Nian-song;FAN Ying(Department of Nephrolog,Shanghai Jiaotong University Affiliated Sixth People's Hospital,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院肾内科,上海200233

出　　处：《世界临床药物》2020年第10期764-769,795,共7页World Clinical Drug

基　　金：国家自然基金面上项目(81670657、81870504、81870468);上海交通大学医学院“临床专职科研队伍”人才计划(20192833);交通大学医工交叉面上项目基金(YG2017MS10)。

摘　　要：糖尿病(diabetes mellitus,DM)是一个重大的全球性健康问题,糖尿病肾病(diabetic nephropathy,DN)是其常见的微血管并发症之一,也是导致终末期肾脏病(end stage renal disease,ESRD)的主要原因。新型降糖药物如胰高血糖素样肽-1受体激动剂(glucagon like peptide-1 receptor agonist,GLP-1RA),在临床用于DM患者降糖的一线治疗。近年来越来越多的研究表明,GLP-1RA具有独立于降糖作用之外的肾脏保护作用。本文就GLP-1RA的发展和其对肾脏保护作用的临床研究作一综述,为临床医生提供更多的参考信息。Diabetes mellitus (DM) is a major global health problem.Diabetic nephropathy (DN) is one of the most common microvascular complications,and also the main cause of end stage renal disease (ESRD).New hypoglycemic drugs,such as glucagon like peptide-1 receptor agonist (GLP-1RA),are the first-line treatment of diabetic patients.In recent years,more and more studies have shown that GLP-1RA had renal protective effect independent of hypoglycemic effect.The development of GLP-1RA and its clinical research on renal protection were elaborated in this review to provide more information for clinicians.

关 键 词：糖尿病 糖尿病肾病 胰高血糖素样肽-1受体激动剂 

分 类 号：R692[医药卫生—泌尿科学] R977.24[医药卫生—外科学]